This site uses cookies, so that our service can work better. I understand

Paul Lingor

Session:
Closing Lecture

Institute:
Technische UniversitĂ€t MĂŒnchen, Munich, Germany;
LingorLab, Department of Neurology, University Medical Center, Georg-August-UniversitÀt Göttingen, Göttingen, Germany
 
 

Website:
http://lingorlab.uni-goettingen.de
https://loop.frontiersin.org/people/35459/overview
Biography:

Paul Lingor is the Associate Professor for Neurology and Deputy Director at the Dept. of Neurology, University Medicine Göttingen. He received his PhD at the Institute for Anatomy and Cell Biology at the Ruprecht-Karls-University Heidelberg. His research interests include disease mechanisms in neurodegeneration: axonal degeneration, regeneration failure, role of transition metals and oxidative stress, physiological and pathophysiological role of alpha- synuclein: autophagy, axonal transport. Moreover, he is interested in translational trials for disease-modi cation in neurodegenerative disorders: novel and repurposed drugs for the treatment of ALS and PD. Prof. Lingor was awarded many times in his career, i.a. Young 31 Researcher Award of the Dept. of Neurology of the University Medicine Göttingen in 2012, Else Kröner Fresenius excellence stipend by the Else Kröner Fresenius Foundation in 2013 and Hans Jörg Weitbrecht Prize for Clinical Neurosciences in 2017. He issued a patent „Rho Kinase Inhibitors for Use in Treating Amyotrophic Lateral Sclerosis“, European patent: 2825175.

Abstract:

"Disease-modifying therapeutic strategies for neurodegenerative disorders: From bench to bedside – can it work?"

Neurodegenerative diseases affect a growing number of people in industrialized countries with aging populations. In addition to increasing socioeconomic costs, they represent a burden on patients, relatives and care givers. Parkinson’s disease (PD) and Amyotrophic lateral sclerosis (ALS) are exemplary neurodegenerative disorders with distinct clinical features and numerous molecular similarities. In this talk I will set the work of our lab on ALS and PD in context and discuss how we analyze axonal degeneration in vitro and in vivo, identify biomarker candidates from various human sources and finally translate preclinical findings to a therapeutic trial in humans.